Walmart Settles Federal Lawsuit Over Opioid Prescription Practices

Walmart Inc. has reached a settlement with the U.S. Department of Justice, resolving a 2020 lawsuit that accused the retail giant of fueling the national opioid crisis by unlawfully dispensing prescriptions from its thousands of in-store pharmacies. The Justice Department confirmed the settlement on Friday, though the financial terms were not immediately made public.

Details of the Agreement

The settlement concludes a significant legal challenge brought against a single company by the federal government over the opioid epidemic. In a statement, a Justice Department spokesperson said the department was "pleased to have reached a settlement with Walmart resolving allegations that its pharmacies failed to comply with their obligations under the Controlled Substances Act."

Walmart also issued a statement, saying, "We are pleased to resolve this matter and will continue supporting the exceptional work our pharmacists do every day to provide outstanding patient care." For investors, the settlement removes a major legal overhang, although the financial impact remains unclear without the disclosure of terms.

Background of the Lawsuit

The Department of Justice originally sued Walmart in 2020, alleging the company had violated the federal Controlled Substances Act since 2013 by failing to properly vet prescriptions. The government had argued at the time that Walmart could be liable for billions of dollars in civil penalties.

Ad

The case was narrowed in March 2024 when a U.S. District Judge dismissed claims that Walmart failed to report suspicious prescriptions to the Drug Enforcement Administration. However, the court allowed the government to pursue a claim that Walmart pharmacists dispensed prescriptions that its own compliance personnel knew were invalid.

Broader Litigation Context

This federal settlement is separate from a previous, larger agreement. In 2022, Walmart agreed to pay $3.1 billion to resolve thousands of lawsuits filed by state, local, and tribal governments over its role in the opioid crisis. The broader litigation has also targeted other major corporations, including drug manufacturer Purdue Pharma and wholesaler Cencora.

The widespread legal actions address a public health crisis that has had a devastating impact. According to the U.S. Centers for Disease Control and Prevention, more than 905,000 people died from opioid overdoses in the United States between 1999 and 2025.